Sialic acids in biological and therapeutic processes: Opportunities and challenges

Future Medicinal Chemistry

Volumn 7, Issue 16, 2015, Pages 2285-2299

  Bauer, Julia ^a   Osborn, Helen M I ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIMOSIAMOSE; CANCER VACCINE; CARBOHYDRATE ANTIGEN; CGP 69669A; DOXORUBICIN; GEMTUZUMAB; OSELTAMIVIR; RIVIPANSEL; SELECTIN ANTAGONIST; SIALIC ACID DERIVATIVE; UNCLASSIFIED DRUG; ZANAMIVIR; CARBOHYDRATE;

ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CLINICAL PRACTICE; CYCLOADDITION; DRUG DELIVERY SYSTEM; DRUG STRUCTURE; HUMAN; INNATE IMMUNITY; MEDICINAL CHEMISTRY; NATURAL KILLER CELL; NEOPLASM; PRIORITY JOURNAL; REVIEW; SIALYLATION; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; IMMUNITY; METABOLISM; NEOPLASMS;

ANIMALS; CARBOHYDRATES; CHEMISTRY, PHARMACEUTICAL; DRUG DISCOVERY; HUMANS; IMMUNITY; NEOPLASMS; SIALIC ACIDS;

EID: 84947553866     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.135     Document Type: Review

References (43)

1. Marth JD, Grewal PK. Mammalian glycosylation in immunity. Nat. Rev. Immunol. 8(11), 874-887 (2008).
2. Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell 126(5), 855-867 (2006).
3. Dube DH, Bertozzi CR. Glycans in cancer and inflammation. Potential for therapeutics and diagnostics. Nat. Rev. Drug Discov. 4(6), 477-488 (2005).
4. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 5, 526-542 (2005).
5. Galan MC, Benito-Alifonso D, Watt GM. Carbohydrate chemistry in drug discovery. Org. Biomol. Chem. 9(10), 3598-3610 (2011).
6. Bernardes GJL, Castagner B, Seeberger PH. Combined approaches to the synthesis and study of glycoproteins. ACS Chem. Biol. 4(9), 703-713 (2009).
7. Chen X, Varki A. Advances in the biology and chemistry of sialic acids. ACS Chem. Biol. 5(2), 163-176 (2010).
8. Schauer R. Achievements and challenges of sialic acid research. Glycoconj. J. 17(7-9), 485-499 (2000).
9. Schauer R. Sialic Acids: Chemistry, Metabolism And Function. Springer-Verlag, Wien-New York (1982).
10. Varki A. Sialic acids in human health and disease. Trends Mol. Med. 14(8), 351-360 (2008).
11. Hudak JE, Canham SM, Bertozzi CR. Glycocalyx engineering reveals a siglec-based mechanism for NK cell immunoevasion. Nat. Chem. Biol. 10, 69-77 (2014).
12. Chokhawala HA, Huang SS, Lau K et al. Combinatorial chemoenzymatic synthesis and high-throughput screening of sialosides. ACS Chem. Biol. 3(9), 567-576 (2008).
13. Crocker PR, Varki A. Siglecs in the immune system. Immunology 103(2), 137-145 (2001).
14. Stevens J, Blixt O, Paulson JC, Wilson IA. Glycan microarray technologies: tools to survey host specificity of influenza viruses. Nat. Rev. Microbiol. 4(11), 857-864 (2006).
15. Varki A, Cummings RD, Esko JD et al. Essentials of Glycobiology. Cold Spring Harbour Press, CA, USA (2008).
16. Rao FV, Rich JR, Rakic B et al. Structural insight into mammalian sialyltransferases. Nat. Struct. Mol. Biol. 16(11), 1186-1188 (2009).
17. Rillahan C, Schwartz E, Rademacher C et al. On-chip synthesis and screening of a sialoside library yields a high affinity ligand for siglec-7. ACS Chem. Biol. 8, 1417-1422 (2013).
18. Macauley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat. Rev. Immunol. 14, 653-666 (2014).
19. Cazet A, Julien S, Bobowski M, Burchell J, Delannoy P. Tumour-associated carbohydrate antigens in breast cancer. Breast Cancer Res. 12(3), 204 (2010).
20. Cazet A, Julien S, Bobowski M et al. Consequences of the expression of sialylated antigens in breast cancer. Carbohydr. Res. 345(10), 1377-1383 (2010).
21. Ernst B, Magnani JL. From carbohydrate leads to glycomimetic drugs. Nat. Rev. Drug Discov. 8(8), 661-677 (2009).
22. Lowe JB, Marth JD. A genetic approach to mammalian glycan function. Annu. Rev. Biochem. 72, 643-691 (2003).
23. Filser C, Kowalczyk D, Jones C et al. Synthetic glycopeptides from the e-selectin ligand 1 with varied sialyl lewis(x) structure as cell-adhesion inhibitors of E-selectin. Angew. Chem. Int. Ed. Engl. 46(12), 2108-2111 (2007).
24. Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat. Rev. Drug Discov. 10(12), 890-890 (2011).
25. Clinical Trials Database www.clinicaltrials.gov
26. Watz H, Bock D, Meyer M et al. Inhaled pan-selectin antagonist bimosiamose attenuates airway inflammation in COPD. Pulm. Pharmacol. Ther. 26(2), 265-270 (2013).
27. Mesch S, Moser D, Strasser DS et al. Low molecular weight antagonists of the myelin-associated glycoprotein: synthesis, docking, and biological evaluation. J. Med. Chem. 53(4), 1597-1615 (2010).
28. Magano J. Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza. Chem. Rev. 109(9), 4398-4438 (2009).
29. Pera NP, Branderhorst HM, Kooij R et al. Rapid screening of lectins for multivalency effects with a glycodendrimer microarray. Chembiochem 11(13), 1896-1904 (2010).
30. Chen WC, Sigal DS, Saven A, Paulson JC. Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22. Leuk. Lymphoma 53(2), 208-210 (2012).
31. Chen WC, Kawasaki N, Nycholat CM et al. Antigen delivery to macrophages using liposomal nanoparticles targeting sialoadhesin/CD169. PloS ONE 7(6), e39039 (2012).
32. Blixt O, Han SF, Liao L et al. Sialoside analogue arrays for rapid identification of high affinity siglec ligands. J. Am. Chem. Soc. 2130(21), 6680-6681 (2008).
33. Rillahan CD, Macauley MS, Schwartz E et al. Disubstituted sialic acid ligands targeting siglecs CD33 and CD22 associated with myeloid leukaemias and B cell lymphomas. Chem. Sci. 5, 2398-2406 (2014).
34. Jandus C, Simon H-U, Von Gunten S. Targeting siglecs-A novel pharmacological strategy for immuno-and glycotherapy. Biochem. Pharmacol. 82(4), 323-332 (2011).
35. O'Reilly MK, Paulson JC. Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol. Sci. 30(5), 240-248 (2009).
36. US FDA. www.fda.gov
37. Zhu J, Wan Q, Ragupathi G, George CM, Livingston PO, Danishefsky SJ. Biologics through chemistry: total synthesis of a proposed dual-acting vaccine targeting ovarian cancer orchestration of oligosaccharide and polypeptide domains. J. Am. Chem. Soc. 131(11), 4151-4158 (2009).
38. Zhu J, Warren JD, Danishefsky SJ. Synthetic carbohydratebased anticancer vaccines: The Memorial Sloan-Kettering experience. Expert Rev. Vaccines 8(10), 1399-1413 (2009).
39. Astronomo RD, Burton DR. Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat. Rev. Drug Disov. 9(4), 308-324 (2010).
40. Zeichner SB. The failed theratope vaccine: 10 years later. J. Am. Osteopath. Assoc. 112(8), 482-483 (2012).
41. Wilson RM, Danishefsky SJ. A vision for vaccines built from fully synthetic tumor-associated antigens: from the laboratory to the clinic. J. Am. Chem. Soc. 135, 14462-14472 (2013).
42. Danishefsky SJ, Shue Y-K, Chang C-H. Development of Globo-H cancer vaccine. Acc. Chem. Res. 48, 643-652 (2015).
43. Byrne B, Donohoe GG, O'Kennedy R. Sialic acids: carbohydrate moieties that influence the biological and physical properties of biopharmaceutical proteins and living cells. Drug Discov. Today 12(7-8), 319-326 (2007).